Welcome to our dedicated page for Omada Health SEC filings (Ticker: OMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
Omada Health, Inc. is reported to have 3,444,630 shares held by Cigna Ventures, LLC and attributable to The Cigna Group, representing 5.8% of the common stock as of 06/30/2025. The filing lists shared voting and dispositive power over those shares. The statement is signed by company officers on 06/23/2026.
OMDA submitted a Form 144 notice reporting a proposed sale of 2,083 shares of common stock related to the exercise of stock options, scheduled 06/22/2026 and to be effected in cash. The filing records prior 10b5-1 sales of 6,894 shares on 06/12/2026.
OMDA reported an insider sale notice for 06/22/2026 covering 17,950 shares of Common Stock tied to an exercise of stock options. The filing also discloses prior 10b5-1 sales of 6,800 shares on 06/15/2026 for $117,183.72.
The 06/22/2026 entry lists the method as an option exercise with cash proceeds; the 10b5-1 trades were executed by Steven L. Cook. Timing and proceeds treatment are stated in the notice.
Omada Health, Inc. director Trevor Fetter reported an equity award and updated holdings. He received 10,882 shares of Common Stock as a grant, represented by restricted stock units (RSUs) with a grant price of $0.00 per share. Each RSU converts into one share upon vesting.
According to the footnotes, 100% of these RSUs will vest on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of Omada Health stockholders, subject to his continued service. Following the award, he directly holds 23,533 shares and indirectly holds 111,200 shares through a family trust where he is a trustee and beneficiary.
Omada Health, Inc. director Jeryl L. Hilleman received an equity grant in the form of restricted stock units. The award covers 10,882 shares of Common Stock, with no cash paid per share. After this grant, Hilleman directly holds 25,220 shares.
The RSUs convert into one share of Common Stock each as they vest. According to the terms, 100% of the RSUs vest on the earlier of the first anniversary of the grant date or the date of the company’s 2027 Annual Meeting of stockholders, subject to continued service through that date.
Stavisky Adam reported acquisition or exercise transactions in this Form 4 filing.
Omada Health, Inc. director Adam Stavisky reported receiving a grant of 10,882 restricted stock units (RSUs), each convertible into one share of Common Stock at no cost when vested.
All RSUs vest 100% on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting, subject to continued service, bringing his direct holdings to 20,618 shares.
Omada Health, Inc. director Jonathan D. Root received a grant of 10,882 restricted stock units, representing a stock-based compensation award with no cash purchase price. These RSUs convert into one share of common stock each upon vesting, with all units vesting on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders, subject to continued service. Following this grant, Root holds 191,057 shares of common stock.
Klapstein Julie D reported acquisition or exercise transactions in this Form 4 filing.
Omada Health, Inc. director Julie D. Klapstein received a grant of 10,882 restricted stock units, each representing one share of Common Stock at no purchase price. Following this award, she holds 21,316 shares directly. The RSUs vest 100% on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders, subject to continued service.
Omada Health, Inc. director Anne Beal received a grant of 10,882 shares of Common Stock in the form of restricted stock units (RSUs). The RSUs have no cash exercise price and will convert into one share of Common Stock per unit when they vest.
According to the award terms, 100% of the RSUs will vest on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of stockholders, if she continues in service through that date. After this grant, Beal directly holds 20,618 shares of Omada Health common stock.
Jain Sachin H. reported acquisition or exercise transactions in this Form 4 filing.
Omada Health, Inc. director Sachin H. Jain received a grant of 10,882 restricted stock units, each convertible into one share of Common Stock upon vesting. After this award, he holds 20,618 shares of Common Stock directly. The RSUs vest 100% on the earlier of the first anniversary of the grant date or the date of Omada Health’s 2027 Annual Meeting of stockholders, contingent on his continued service through that vesting date.